Funding for this research was provided by:
Hjärnfonden (na)
Greta och Johan Kocks stiftelser (na)
Skånes universitetssjukhus (na)
Demensförbundet (na)
Torsten Söderbergs Stiftelse (na)
Article History
Received: 31 October 2019
Accepted: 29 December 2019
First Online: 9 January 2020
Ethics approval and consent to participate
: All procedures performed in studies involving the SATS participants were in accordance with the Helsinki Declaration. The SATS protocol and the present analyses of data were submitted to and approved by the Regional Ethical Review Board, Lund University, Lund, Sweden, no 2014/658, dated 9 December 2014. Written informed consent was obtained from all patients included in the SATS. If an individual was not able to provide consent for him/herself, consent was obtained from their closest relative.
: Not applicable.
: CW has no competing interests. KB has served as a consultant or on advisory boards for Alzheon, Biogen, Eli Lilly, Fujirebio Europe, IBL International and Roche Diagnostics and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg. OH has received research support (to the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals, Fujirebio, and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Eli Lilly, Roche and Fujirebio.